American Journal of Medical Case Reports
ISSN (Print): 2374-2151 ISSN (Online): 2374-216X Website: Editor-in-chief: Samy, I. McFarlane
Open Access
Journal Browser
American Journal of Medical Case Reports. 2020, 8(7), 189-191
DOI: 10.12691/ajmcr-8-7-8
Open AccessCase Report

Dyshidrotic Eczema Associated with Contraceptive Tubal Occlusion Device

Amandeep S Kataria1, , Hemadhanvi Chagarlamudi1, Hanna Lateef2, Benjamin J Farley1, Aazim Arif1, Tien-Anh N. Tran3 and Farooq Lateef1, 2

1Florida State University College of Medicine, Tallahassee, FL, U.S.A.

2Orlando Dermatology, Orlando, FL, U.S.A.

3AdventHealth Orlando, Department of Pathology, Orlando, FL, U.S.A.

Pub. Date: April 19, 2020

Cite this paper:
Amandeep S Kataria, Hemadhanvi Chagarlamudi, Hanna Lateef, Benjamin J Farley, Aazim Arif, Tien-Anh N. Tran and Farooq Lateef. Dyshidrotic Eczema Associated with Contraceptive Tubal Occlusion Device. American Journal of Medical Case Reports. 2020; 8(7):189-191. doi: 10.12691/ajmcr-8-7-8


Nickel-related hypersensitivity reactions associated with the Essure micro-insert (Contraceptive Tubal Occlusion Device and Delivery System) are extremely rare, with only four reports in the current literature. We present a case of a 37-year-old woman who presented to our clinic for initial dermatologic evaluation of dermatitis localized to both hands three years after device placement. A diagnosis of dyshidrotic eczema, classically associated with systemic nickel exposure, was made after careful clinical and histopathologic evaluation. The micro-insert contraceptive device was suspected as the cause given our patient’s self-reported history of nickel allergy, which was further supported by positive patch test results. Currently, our patient has seen significant improvement in her condition with topical steroids and occasional intralesional steroid injections. This case represents a diagnostic challenge given the presentation of a seemingly localized dermatitis secondary to systemic nickel exposure from a distant source. In addition, the delayed development of our patient’s rash posed a clinical challenge in drawing a causal relationship between device placement and her allergic reaction. Practitioners should be cognizant of eliciting a history of implanted devices (plates, screws, implants, endovascular prostheses etc.) for all patients, even if the allergic reaction is seemingly localized such as dyshidrotic eczema.

eczema dermatitis contraceptive device contraception tubal occlusion device

Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit


[1]  Zurawin RK, Zurawin JL. Adverse events due to suspected nickel hypersensitivity in patients with Essure micro-inserts. J Minim Invasive Gynecol. 2011 Jul-Aug; 18(4): 475-82.
[2]  Nishizawa A. Dyshidrotic Dermatitis and Its Relationship to Metal Allergy. Curr Probl Dermatol. 2016; 51: 80-5.
[3]  Wollina U. Pompholyx: a review of clinical features, differential diagnosis, and management. Am J Clin Dermatol. 2010; 11(5): 305-14.
[4]  Lane A, Tyson A, Thurston E. Providing Re-Essure-ance to the Nickel-Allergic Patient Considering Hysteroscopic Sterilization. J Minim Invasive Gynecol. 2016 Jan; 23(1): 126-9.
[5]  Bibas N, Lassere J, Paul C, Aquilina C, Giordano-Labadie F. Nickel-induced systemic contact dermatitis and intratubal implants: the baboon syndrome revisited.Dermatitis. 2013 Jan-Feb; 24(1): 35-6.
[6]  Al-Safi Z, Shavell VI, Katz LE, Berman JM. Nickel hypersensitivity associated with an intratubal microinsert system. Obstet Gynecol. 2011 Feb; 117 (2 Pt 2): 461-2.
[7]  Baltus T, Brown J, Mahmoud I. Delayed systemic allergic dermatitis following Essure insert: A case report. Case Rep Womens Health. 2018 Oct; 20: e00075.
[8]  U.S. Food and Drug Administration, FDA Activities: Essure,
[9]  Lessard CR, Hopkins MR. Efficacy, safety, and patient acceptability of the Essure procedure. Patient Prefer Adherence. 2011; 5: 207-212. Published 2011 Apr 28.
[10]  Markel K, Brod B, Jacob SE. Letter to the Editor: Metal hypersensitivity reactions in the context of Essure. Case Rep Womens Health. 2018 Oct; 20: e00087.